New Paths in Predictive Payer Coverage: Insights drawing from historical metrics that optimize pre- and post-commercialization marketing efforts for new therapies

Before going to market with a new drug, medical device or test, it’s crucial to know how payers will treat it post-approval. Understanding postlaunch coverage restrictions and knowing which payers are likely to publish policy in the first six months to two years allows organizations to design effective marketing strategies. But who has a crystal ball to discern the future? How can anyone predict the response to a launch?

About TrialCard
TrialCard Incorporated provides patient affordability, medication access and adherence, patient support, and clinical trial services on behalf of pharmaceutical manufacturers. Founded in 2000, TrialCard has connected nearly 33 million patients with over $15 billion in branded drug savings to date. Our attention to detail, commitment to our clients, and locations in areas that are rich in healthcare talent allow us to provide levels of service that are unsurpassed in our industry. The company is headquartered in Morrisville, North Carolina. For more information about TrialCard, please visit